Patients with poorly controlled allergic rhinitis (AR) experience nasal and ocular symptoms, and suffer from sleep disturbances, emotional problems, and activity impairment. In patients with more severe disease, AR is often associated with impaired quality of life (QOL). MP-AzeFlu (137 µg azelastine hydrochloride/50 µg fluticasone propionate intranasal spray) is safe and effective, but the impact on QOL among patients with AR requires further real-world investigation. The main objective of this observational study was to evaluate changes in patient sleep quality and trouble with daily work and social activities after ~14 days of treatment with MP-AzeFlu in routine clinical practice.
|Publication status||Published - 6 Jun 2020|
|Event||EAACI Digital Congress 2020 - Digital, London, United Kingdom|
Duration: 6 Jun 2020 → 8 Jun 2020
|Conference||EAACI Digital Congress 2020|
|Period||6/06/20 → 8/06/20|